Alcon Inc. (ALC)
 NYSE: ALC · Real-Time Price · USD
 74.26
 +0.66 (0.90%)
  At close: Oct 30, 2025, 4:00 PM EDT
74.78
 +0.52 (0.70%)
  Pre-market: Oct 31, 2025, 4:26 AM EDT
Alcon Revenue
Alcon had revenue of $2.60B in the quarter ending June 30, 2025, with 4.01% growth. This brings the company's revenue in the last twelve months to $10.03B, up 4.04% year-over-year. In the year 2024, Alcon had annual revenue of $9.91B with 4.82% growth.
Revenue (ttm) 
 $10.03B
Revenue Growth 
 +4.04%
P/S Ratio 
 3.68
Revenue / Employee 
 $391,617
Employees 
 25,599
Market Cap 
36.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 9.91B | 456.00M | 4.82% | 
| Dec 31, 2023 | 9.46B | 738.00M | 8.47% | 
| Dec 31, 2022 | 8.72B | 426.00M | 5.14% | 
| Dec 31, 2021 | 8.29B | 1.46B | 21.34% | 
| Dec 31, 2020 | 6.83B | -675.00M | -8.99% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| Eli Lilly and Company | 59.42B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
ALC News
- 1 day ago - Harding Loevner International Equity ADR Q3 2025 Portfolio Update - Seeking Alpha
- 3 days ago - STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon - Business Wire
- 6 days ago - Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon - Business Wire
- 6 days ago - Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction - Business Wire
- 7 days ago - Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders - Business Wire
- 10 days ago - Yunqi Capital Issues Letter to STAAR Surgical's Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction - Business Wire
- 10 days ago - Broadwood Partners Highlights Growing Opposition to STAAR Surgical's Proposed Sale to Alcon - Business Wire
- 13 days ago - Broadwood Partners Issues Letter to STAAR Surgical's Board Urging it to Allow Timely Shareholder Vote on Alcon Sale - Business Wire